Contact
searchSearch
HMP Global

Prostate Cancer

Scott Tagawa, MD
Videos
Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer
10/30/2025
Scott Tagawa, MD
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell...
10/30/2025
Radiopharmaceutical Education Institute
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Radiopharmaceutical Education Institute
Conference Coverage
[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer
02/13/2025
Allison Casey
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of...
02/13/2025
Oncology
News
Sequencing of 177Lu-PSMA-617 and Cabazitaxel Did Not Significantly Impact Survival for Patients With Metastatic Castration-Resistant Prostate Cancer
01/21/2025
Stephanie Holland
According to results from the LuCaS trial, the sequence in which 177Lu-PSMA-617 and cabazitaxel was administered did not significantly impact survival outcomes among patients with metastatic castration-resistant prostate cancer.
According to results from the LuCaS trial, the sequence in which 177Lu-PSMA-617 and cabazitaxel was administered did not significantly impact survival outcomes among patients with metastatic castration-resistant prostate cancer.
According to results from the...
01/21/2025
Oncology
Quiz
Adaptive 177Lu-PSMA-617 Dosing in the ENZA-p Trial
11/10/2023
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this quiz on the adaptive dosing utilized in the ENZA-p trial, evaluating the addition of 177Lu-PSMA-617 to enzalutamide for patients with metastatic castration-resistant prostate cancer.
Test your knowledge with this...
11/10/2023
Oncology
Philip Kuo, MD, PhD, University of Arizona Cancer Center
Videos
Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Philip Kuo, MD, PhD
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares...
11/10/2023
Oncology
News
Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer
11/06/2023
Allison Casey
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.
A phase 2 study found that...
11/06/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos

177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
10/25/2023
Oliver Sartor, MD
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress,...
10/25/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos
Identifying Biomarkers to Predict Resistance to Lutetium-177–PSMA-617
10/11/2023
Oliver Sartor, MD
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver...
10/11/2023
Oncology

Advancing Oncology Through Radiopharmaceutical Science and Innovation

The Radiopharmaceutical Education Institute (RPEI) will bridge the gap between research, clinical application, and patient care by delivering accessible, multidisciplinary expert insights and education on radiopharmaceuticals in oncology to our engaged national audience of oncologists, oncology advanced practitioners, oncology nurses, diagnostic radiologists, and nuclear medicine specialists.

The Oncology Learning Network and RPEI are also the official digital platforms for our Great Debates & Updates: Solid Tumor live meeting.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use